Sedlak Tara, Izadnegahdar Mona, Humphries Karin H, Bairey Merz C Noel
Vancouver General Hospital, Vancouver, British Columbia, Canada.
Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.
Can J Cardiol. 2014 Jul;30(7):747-755. doi: 10.1016/j.cjca.2013.08.013. Epub 2014 Feb 27.
In women presenting for evaluation of suspected ischemic symptoms, a diagnosis of normal coronary arteries is 5 times more common than it is in men. These women are often labelled as having cardiac syndrome X, and a subset of them have microvascular angina caused by microvascular coronary dysfunction (MCD). MCD is not benign and is associated with an annual 2.5% cardiac event rate. Noninvasive testing for MCD remains insensitive, although newer imaging modalities, such as adenosine cardiac magnetic resonance imaging, appear promising. The gold standard for diagnosis of MCD is coronary reactivity testing, an invasive technique that is not available in many countries. With regard to treatment, large-scale trials are lacking. Although research is ongoing, the current platform of therapy consists of antiangina, antiplatelet, and endothelium-modifying agents (primarily angiotensin-converting enzyme inhibitors and statins).
在因疑似缺血症状前来评估的女性中,冠状动脉正常的诊断比男性常见5倍。这些女性常被标记为患有心脏综合征X,其中一部分人患有由微血管冠状动脉功能障碍(MCD)引起的微血管性心绞痛。MCD并非良性疾病,每年有2.5%的心脏事件发生率与之相关。对MCD的无创检测仍然不够敏感,尽管诸如腺苷心脏磁共振成像等更新的成像方式似乎很有前景。MCD诊断的金标准是冠状动脉反应性检测,这是一种侵入性技术,在许多国家无法进行。关于治疗,缺乏大规模试验。尽管研究仍在进行,但目前的治疗方案包括抗心绞痛、抗血小板和内皮修饰剂(主要是血管紧张素转换酶抑制剂和他汀类药物)。